PDF(Pubmed)
Abstract：
As treatments with BTK inhibitors and BCL2 inhibitors have replaced the use of chemoimmunotherapy in CLL in both first-line and relapsed patients, it becomes critical to rationalize their use and exploit the full potential of each drug. Despite their proven, robust, and manifest efficacy, BTKis and BCL2is fail to provide long-term disease control in some categories of patients, and to date this is an unmet clinical need that is critical to recognize and address. Ongoing clinical trials are evaluating new treatment algorithms and new molecules to progressively thin this population. In this review for each category of patients we explicate the different possible patterns of treatment sequencing based on currently available evidence, starting from the frontline to currently ongoing trials, in order to optimize therapies as much as possible.
摘要：
由于BTK抑制剂和BCL2抑制剂的治疗已经取代了一线和复发患者在CLL中使用化学免疫疗法，合理化其使用并充分利用每种药物的潜力变得至关重要。尽管他们已经证明，健壮,和明显的功效，BTKis和BCL2is未能在某些类别的患者中提供长期疾病控制，迄今为止，这是一个尚未满足的临床需求，对识别和解决至关重要。正在进行的临床试验正在评估新的治疗算法和新分子，以逐步减少这一人群。在这篇综述中，针对每个类别的患者，我们根据目前可用的证据阐述了不同的治疗测序可能模式，从前线开始到目前正在进行的试验，以尽可能优化治疗。
